PXL770

Phase 2Small molecule

PPoxel SA

PXL770 is one of 7 small molecule programs targeting X-linked adrenoleukodystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

X-Linked AdrenoleukodystrophyActive, not recruiting

X-Linked AdrenoleukodystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in X-Linked Adrenoleukodystrophy

#DrugCompanyPhaseTrials

Actos

Mirapex

PXL065

1 4

MIN-102

MMinoryx Therapeutics, S.L.

Phase 2

1 5

PXL770

PPoxel SA

Phase 2

1 6

Bezafibrate

IIntercept Pharmaceuticals

Preclinical

1 7

Sobetirome

NNeuroVia, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

X-linked adrenoleukodystrophy1 trial

Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

Withdrawn·PPoxel SA·Phase 2·NCT05146284

Treatment1 trial

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

Completed·PPoxel SA·Phase 1·NCT03950882·17 enrolled

Efficacy and Safety1 trial

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Completed·PPoxel SA·Phase 2·NCT03763877·121 enrolled

Tics1 trial

Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

Completed·PPoxel SA·Phase 1·NCT05441904·16 enrolled

Unspecified1 trial

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

Completed·PPoxel SA·Phase 1·NCT03395470·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PXL770. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PXL770 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PXL770. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Poxel SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPoxel SA

PXL770

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

X-linked adrenoleukodystrophy1 trial

Treatment1 trial

Efficacy and Safety1 trial

Tics1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News